Evidence map›Paper›PMID 29268702›Full record

ArticleBMC family practice2017

Assessing and improving organizational readiness to implement substance use disorder treatment in primary care: findings from the SUMMIT study.

Allison J Ober, Katherine E Watkins, Sarah B Hunter, Brett Ewing, Karen Lamp, Mimi Lind, Kirsten Becker, Keith Heinzerling, Karen C Osilla, Allison L Diamant and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC family practice, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
7.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 41 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Allison J OberRAND Corporation, 1776 Main Street, Santa Monica, CA, 90407, USA. ober@rand.org.ORCID 0000-0001-9333-0225
Katherine E WatkinsRAND Corporation, 1776 Main Street, Santa Monica, CA, 90407, USA.
Sarah B HunterRAND Corporation, 1776 Main Street, Santa Monica, CA, 90407, USA.
Brett EwingRAND Corporation, 1776 Main Street, Santa Monica, CA, 90407, USA.
Karen LampVenice Family Clinic, 2509 Pico Boulevard, Santa Monica, CA, 90405, USA.
Mimi LindVenice Family Clinic, 2509 Pico Boulevard, Santa Monica, CA, 90405, USA.
Kirsten BeckerRAND Corporation, 1776 Main Street, Santa Monica, CA, 90407, USA.
Keith HeinzerlingUCLA Department of Family Medicine, UCLA Family Health Center, 1920 Colorado Avenue, Santa Monica, CA, 90404, USA.
Karen C OsillaRAND Corporation, 1776 Main Street, Santa Monica, CA, 90407, USA.
Allison L DiamantRAND Corporation, 1776 Main Street, Santa Monica, CA, 90407, USA.
Claude M SetodjiRAND Corporation, 1776 Main Street, Santa Monica, CA, 90407, USA.
RAND Corporation · USVenice Family Clinic · USUCLA Health · US

Funding

Integrated Collaborative Care for Substance Use DisordersR01DA034266 · NIDA · RAND CORPORATION · PI WATKINS, KATHERINE E · 2012 to 2016
$4.0M
NIDA NIH HHS 1R01DA034266NIDA NIH HHS R01 DA034266
6 · The paper itself

Abstract

backgroundMillions of people with substance use disorders (SUDs) need, but do not receive, treatment. Delivering SUD treatment in primary care settings could increase access to treatment because most people visit their primary care doctors at least once a year, but evidence-based SUD treatments are underutilized in primary care settings. We used an organizational readiness intervention comprised of a cluster of implementation strategies to prepare a federally qualified health center to deliver SUD screening and evidence-based treatments (extended-release injectable naltrexone (XR-NTX) for alcohol use disorders, buprenorphine/naloxone (BUP/NX) for opioid use disorders and a brief motivational interviewing/cognitive behavioral -based psychotherapy for both disorders). This article reports the effects of the intervention on key implementation outcomes.

methodsTo assess changes in organizational readiness we conducted pre- and post-intervention surveys with prescribing medical providers, behavioral health providers and general clinic staff (N = 69). We report on changes in implementation outcomes: acceptability, perceptions of appropriateness and feasibility, and intention to adopt the evidence-based treatments. We used Wilcoxon signed rank tests to analyze pre- to post-intervention changes.

resultsAfter 18 months, prescribing medical providers agreed more that XR-NTX was easier to use for patients with alcohol use disorders than before the intervention, but their opinions about the effectiveness and ease of use of BUP/NX for patients with opioid use disorders did not improve. Prescribing medical providers also felt more strongly after the intervention that XR-NTX for alcohol use disorders was compatible with current practices. Opinions of general clinic staff about the appropriateness of SUD treatment in primary care improved significantly.

conclusionsConsistent with implementation theory, we found that an organizational readiness implementation intervention enhanced perceptions in some domains of practice acceptability and appropriateness. Further research will assess whether these factors, which focus on individual staff readiness, change over time and ultimately predict adoption of SUD treatments in primary care.

Indexed as

Attitude of Health PersonnelAdultAlcohol-Related DisordersBuprenorphineCognitive Behavioral TherapyDelayed-Action PreparationsDelivery of Health CareFeasibility StudiesFemaleFinancing, GovernmentHumansLos AngelesMaleMiddle AgedMotivational InterviewingNaloxoneBuprenorphineDelayed-Action PreparationsNaloxoneNaltrexoneNarcotic AntagonistsBuprenorphine/naloxoneCare coordinationCollaborative careEvidence-based substance use disorder treatmentExtended-release injectable naltrexoneImplementation interventionMedication-assisted treatmentMotivational interviewingOrganizational readinessPrimary careSuboxone®Vivitrol®

Identifiers

PMID29268702
PMCPMC5740845
OpenAlexW2777430132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.